Novo Nordisk has made another major capital investment in production capacity for its diabetes and obesity therapies, agreeing to spend €2.1 billion ($2.3 billion) on a fa
Novo Nordisk’s obesity therapy Wegovy has cut the risk of death by 19% in the SELECT trial, mirroring the benefits of the drug in cardiovascular outcomes in people who are
Novo Nordisk is leaving nothing to chance when it comes to claiming a stake in the burgeoning market for diabetes and obesity therapies, announcing a plan to spend a whopp
Novo Nordisk is finally facing some major competition to its obesity franchise juggernaut, now that Eli Lilly’s rival therapy tirzepatide has been approved by the FDA as a
Søren Møller, managing partner for seed investments at Novo Holdings, believes successful start-ups in healthcare share a trifecta of component pieces: “great science, the right talent, and